Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04295486 · ClinicalTrials.gov registry record · Phase 2
Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty
A Phase 2 study of Venous Thromboembolism, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 5,478
- Enrollment target
- 1
- Study location
NCT04295486: Recruiting Phase 2 study of Venous Thromboembolism, sponsored by University of Miami.
NCT04295486 is a Phase 2 study of Venous Thromboembolism that is actively recruiting participants, run by University of Miami. The registered enrollment target is 5,478 participants, below the 6,179-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04295486, a Phase 2 study of Venous Thromboembolism, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 5,478 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.
Primary Outcome
Efficacy of prophylaxis will be reported as the number of reported incidence of symptomatic Pulmonary Embolism (PE) and Deep Vein Thrombosis (DVT).
Conditions Studied
Interventions
- DRUG Aspirin
Study Locations (1)
Florida
- University of Miami Hospital - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,478 participants |
| Start Date | 2021-03-01 |
| Est. Completion | 2027-03-01 |
| Phase | Phase 2 |
What NCT04295486 shows while recruiting
NCT04295486 is an interventional study that assigns participants to a tested intervention. Its 5,478 participants enrollment target places it among the larger protocols in the corpus, below the 6,179-participant average among 47 other Venous Thromboembolism trials with a reported enrollment target (11% lower).
The record links to 1 condition, with Venous Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Aspirin is the first listed.
NCT04295486 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04295486 about?
NCT04295486 is a clinical study titled "Optimal Dosing For Low-Dose Aspirin Chemoprophylaxis For VTE Following Total Joint Arthroplasty". This research study is attempting to answer the question of whether 81 mg aspirin once daily is as effective as 81 mg aspirin twice daily in preventing blood clots after total joint replacement surgery.
What is the current status of trial NCT04295486?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 5,478 participants. The study started on 2021-03-01. Estimated completion is 2027-03-01.
What conditions does trial NCT04295486 study?
This clinical trial studies the following conditions: Venous Thromboembolism.
What interventions are being tested in trial NCT04295486?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT04295486?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04295486 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04295486's enrollment target sits among peer trials
5,478 9th of 47 higher than 39 of 47 other Venous Thromboembolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Venous Thromboembolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
ACTIVE NOT RECRUITING · Phase 2
-
Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism
COMPLETED · Phase 2
-
Detecting the Impact of Statin Therapy On Lowering Risk of Venous Thrombo-Embolic Events (DISOLVE)
COMPLETED · Phase 2
-
EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis
COMPLETED · Phase 2
-
Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05952557 · 5,500 participants · Phase 3
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
- NCT06084234 · 5,500 participants · Phase 4
National Liver Cancer Screening Trial
- NCT07146568 · 5,515 participants · NA
Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hospital
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI